ATYs306Q6fE

74
post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J.
2013;34:1489–97.
551. Flory JH, Ky B, Haynes K, S MB, Munson J, Rowan C, Strom BL, Hennessy S.
Observational cohort study of the safety of digoxin use in women with heart
failure. BMJ Open. 2012;2:e000888.
552. Andrey JL, Romero S, Garcia-Egido A, Escobar MA, Corzo R, Garcia-Dominguez G,
Lechuga V, Gomez F. Mortality and morbidity of heart failure treated with
digoxin. A propensity-matched study. Int J Clin Pract. 2011;65:1250–8.
553. Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ,
Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP,
ORBIT-AF Investigators. Digoxin Use and Subsequent Outcomes Among Patients
in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015;65:2691–8.
554. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone
or in combination with digoxin for the management of atrial fibrillation in
patients with heart failure? J Am Coll Cardiol. 2003;42:1944–51.
555. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in
chronic atrial fibrillation during daily activity and programmed exercise:
a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:
304–10.
556. Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH, Kim EJ, Kim SH, Cho SK, Kim
SS. Efficacy and safety of digoxin alone and in combination with low-dose
diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am
J Cardiol. 1995;75:88–90.
557. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol
on heart rate and exercise tolerance in digitalised patients with chronic atrial
fibrillation. J Cardiovasc Pharmacol. 1989;13:1–6.
558. Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K, Inoue H.
Rate control and quality of life in patients with permanent atrial fibrillation: the
Quality of Life and Atrial Fibrillation (QOLAF) Study. Circ J. 2006;70:965–70.
559. ClinicalTrials.gov. Rate Control Therapy Evaluation in Permanent Atrial
Fibrillation (RATE-AF). https://clinicaltrials.gov/ct2/show/NCT02391337 (5 May
2016).
560. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege
HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen
DJ, Van den Berg MP, RACE II Investigators. Lenient versus strict rate control in
patients with atrial fibrillation. N Engl J Med. 2010;362:1363–73.
561. Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JG,
Hillege HL, Tuininga YS, Van Veldhuisen DJ, Ranchor AV, Van Gelder IC, RACE II
Investigators. The effect of rate control on quality of life in patients with
permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in
Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011;58:1795–803.
562. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns
HJ, RACE and AFFIRM Investigators. Does intensity of rate-control influence
outcome in atrial fibrillation? An analysis of pooled data from the RACE and
AFFIRM studies. Europace. 2006;8:935–42.
563. Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace revisited: long
term survival and predictors of permanent atrial fibrillation. Heart.
2003;89:1035–8.
564. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, Weerasooriya R.
Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT
trial. Europace. 2007;9:498–505.
565. Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden
death after radiofrequency catheter ablation of the atrioventricular junction.
Pacing Clin Electrophysiol. 1997;20:343–8.
566. Wang RX, Lee HC, Hodge DO, Cha YM, Friedman PA, Rea RF, Munger TM, Jahangir
A, Srivathsan K, Shen WK. Effect of pacing method on risk of sudden death after
atrioventricular node ablation and pacemaker implantation in patients with
atrial fibrillation. Heart Rhythm. 2013;10:696–701.
567. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh
JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and
systematic review. Circ Arrhythm Electrophysiol. 2012;5:68–76.
568. Bradley DJ, Shen WK. Overview of management of atrial fibrillation in
symptomatic elderly patients: pharmacologic therapy versus AV node ablation.
Clin Pharmacol Ther. 2007;81:284–7.
569. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after
ablation and pacing therapy for atrial fibrillation : a meta-analysis. Circulation.
2000;101:1138–44.
570. Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer
DL, Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation
of the atrioventricular node and implantation of a permanent pacemaker in
patients with atrial fibrillation. N Engl J Med. 2001;344:1043–51.
571. Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchronization
therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and
meta-analysis. Curr Cardiol Rep. 2013;15:330.
572. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N,
Erdmann E. Effect of cardiac resynchronization on the incidence of atrial
fibrillation in patients with severe heart failure. Circulation. 2006;114:18–25.
573. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA,
Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde
C, Mont L, Padeletti L, Sutton R, Vardas PE, Zamorano JL, Achenbach S,
Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R,
Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A,
Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M,
Torbicki A, Wijns W, Windecker S, Kirchhof P, Blomstrom-Lundqvist C, Badano LP,
Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC,
Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H,
McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F,
Tendera M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac pacing
and cardiac resynchronization therapy: the Task Force on cardiac pacing and
resynchronization therapy of the European Society of Cardiology (ESC).
Developed in collaboration with the European Heart Rhythm Association (EHRA).
Eur Heart J. 2013;34:2281–329.
574. Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, Singh JP. Atrioventricular
nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right
ventricular pacing mode. Eur J Heart Fail. 2012;14:661–7.
575. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise
tolerance and cardiac output in atrial fibrillation: the effects of treatment with
digoxin, verapamil and diltiazem. Eur Heart J. 1988;9:777–81.
576. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, Rienstra
M, Van den Berg MP, Van Gelder IC, RACE II Investigators. Digoxin in patients with
permanent atrial fibrillation: data from the RACE II study. Heart Rhythm.
2014;11:1543–50.
577. Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS, In HH, Moon TH, Park GS,
Cho SK, Kim SS. Comparative study of efficacy and safety of low-dose diltiazem
or betaxolol in combination with digoxin to control ventricular rate in chronic
atrial fibrillation: randomized crossover study. Int J Cardiol. 1995;52:167–74.
578. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate
versus rhythm-control strategies in atrial fibrillation: an updated comprehensive
review and meta-analysis. PACE. 2013;36:122–33.
579. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control
in patients with atrial fibrillation: a meta-analysis. Arch Intern Med.
2005;165:258–62.
580. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics
for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane
Database Syst Rev. 2012;5:CD005049.
581. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J,
Dubuc M, Gagne P, Nattel S, Thibault B. Amiodarone to prevent recurrence of
atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med.
2000;342:913–20.
582. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM,
Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser
SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN,
Stevenson LW, Stevenson WG, Thibault B,Waldo AL. Rhythm control versus rate
control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.
583. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM,
Hohnloser SH. Dronedarone for maintenance of sinus rhythm in atrial fibrillation
or flutter. N Engl J Med. 2007;357:987–99.
584. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U,
Samol A, Steinbeck G, Treszl A, Wegscheider K, Breithardt G. Short-term versus
long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation
(Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment
trial. Lancet. 2012;380:238–46.
585. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H,
Kongstad O, Pehrson S, Englund A, Hartikainen J, Mortensen LS, Hansen PS.
Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl
J Med. 2012;367:1587–95.
586. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L,
Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY,
Berry SM, Berry DA, ThermoCool AF Trial Investigators. Comparison of
antiarrhythmic drug therapy and radiofrequency catheter ablation in patients
with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA.
2010;303:333–40.
587. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, Laroche C,
Anselme F, Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse GH, Perez-
Villacastin J, Riahi S, Taborsky M, Theodorakis G, Trines SA, Atrial Fibrillation
Ablation Pilot Study Investigators. The atrial fibrillation ablation pilot study:
a European Survey on Methodology and results of catheter ablation for atrial
fibrillation conducted by the European Heart Rhythm Association. Eur Heart J.
2014;35:1466–78.
588. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C,
Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation.
N Engl J Med. 2009;360:668–78.
589. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC,
Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and
rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–
33.
590. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA,
Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ, Rate Control versus Electrical
Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate
control and rhythm control in patients with recurrent persistent atrial fibrillation.
N Engl J Med. 2002;347:1834–40.
591. Opolski G, Torbicki A, Kosior DA, Szulc M,Wozakowska-Kaplon B, Kolodziej P,
Achremczyk P, Investigators of the Polish How to Treat Chronic Atrial Fibrillation
Study. Rate control vs rhythm control in patients with nonvalvular persistent
atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation
(HOT CAFE) Study. Chest. 2004;126:476–86.
592. Kong MH, Shaw LK, O’Connor C, Califf RM, Blazing MA, Al-Khatib SM. Is
rhythmcontrol superior to rate-control in patients with atrial fibrillation and
diastolic heart failure? Ann Noninvasive Electrocardiol. 2010;15:209–17.
593. Kotecha D, Kirchhof P. Rate and rhythm control have comparable effects on
mortality and stroke in atrial fibrillation but better data are needed. Evid Based
Med. 2014;19:222–3.